In January 2025, the FDA approved Journavx (suzetrigine), a non-opioid drug for moderate to severe acute pain. It acts on peripheral sodium channels, avoiding the addictive risks of opioids. This is the first new class of pain medication approved in over 20 years and shows promise for safer pain management.